Many kids benefit from GLP-1s. What happens when they have to stop taking them?
At the November 2022 Obesity Week in San Diego, it was clear something big was happening. A late-breaking session released results of the STEP TEENS phase IIIa trial, showing 16 percent weight loss in adolescents with obesity treated with once-weekly semaglutide (Wegovy) for 68 weeks. The side effects were manageable and similar to those experienced in adults: nausea, vomiting, and constipation.
A month later, semaglutide received FDA approval for weight management …
Many kids benefit from GLP-1s. What happens when they have to stop taking them?















![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)


![Why loving organizations are the secret to ending burnout in medicine [PODCAST]](https://kevinmd.com/wp-content/uploads/603e9e41-66d6-47f3-a831-f1f9c17489b3-190x100.jpeg)



